ResultsIQ › Latest results › Kwality Pharmaceuticals Limited
Kwality Pharmaceuticals Limited Q2 FY27 results deck summary
NSE: KPL · BSE: 539997
Results deck of 12 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue ₹181.2 cr and PAT ₹29.0 cr, with FY27 revenue guidance raised to ₹720+ cr from ₹700+ cr.
Key takeaways
- Q2 FY27 results Revenue was ₹181.2 cr (Q1 FY27: ₹162.4 cr) and PAT ₹29.0 cr at a 16.0% margin.
- FY27 guidance FY27 revenue guidance was raised to ₹720+ cr from ₹700+ cr, with EBITDA margin of 27-28%+.
- Margin expansion EBITDA margin rose to 27.5% in Q2 FY27 from 25.3% in Q1 FY27.
- Regulated markets EU-GMP certification from Hungary for Cephalosporin and Oncology plants and new LATAM, MENA and GCC registrations drive growth.
- Execution risk Unit 6 commercial production and license audit are still pending, with R&D of molecules 40% complete.
Kwality Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (12 Nov 2026)
- Q1 FY27: Earnings call (10 Aug 2026), Results deck (10 Aug 2026)
- Q4 FY26: Earnings call (19 May 2026), Results deck (19 May 2026)
- Q3 FY26: Results deck (12 Feb 2026)
- Q4 FY25: Results deck (5 Jun 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.